U-M Health again earns nursing’s highest honor through Magnet redesignation

Less than 10% of U.S. hospitals receive the coveted distinction, which identifies organizations that meet rigorous standards for quality patient care, nursing excellence and innovations in professional nursing practice.

Author | Beata Mostafavi

University of Michigan Health nurses continue to be recognized as among the best in the nation, again receiving the highest honor in nursing.

The American Nurses Credentialing Center announced March 17 that U-M Health, of Michigan Medicine, achieved Magnet redesignation. The prestigious Magnet distinction, awarded to less than 10% of U.S. hospitals, recognizes health care organizations for quality patient care and outcomes, nursing excellence and innovations in professional nursing practice.  

U-M Health achieved its first Magnet designation in early 2017 after a rigorous and lengthy process that required widespread participation from leadership and staff and included written patient care documentation, an on-site visit, and a review by the Commission on Magnet Recognition.

Health care organizations must reapply for Magnet recognition every four years based on adherence to Magnet concepts and demonstrated improvements in patient care and quality.  

“Magnet status is the gold standard for nursing excellence and a tremendous honor,” said Chief Nurse Executive Nancy May, DNP. “This well-earned redesignation reflects the extraordinary nursing care at our institution and continues to distinguish us as a place where patients, families and the community can expect the highest level of care.”

The Magnet program provides a framework for nursing practice, research, and measurement of outcomes. The program helps advance nursing standards through ongoing nursing education and career development and disseminating best practices in nursing services to improve patient care.

Redesignation also helps maintain a culture that attracts and retains exceptional nursing professionals.

More to explore

Media Contact
University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories

 microbes inside gut yellow
Health Lab

New oral nanomedicine boosts effectiveness of cancer immunotherapies

University of Michigan researchers developed an oral drug that can increase the ability of T cells to attack tumors. The drug uses the microbial metabolite 3,4-dihydroxybenzoic acid, which is derived from dietary fiber.
 woman itching skin orange blue button down
Health Lab

A first-of-its-kind treatment for mastocytosis

A new drug called Avapritinib achieved longterm safety approval for indolent systemic mastocytosis.
 kid at table not wanting to eat breakfast with parent blurred in background white coloring milk on table
Health Lab

Many parents face challenges getting kids to eat a healthy breakfast before school

Three-quarters of parents report at least one barrier to their child starting the day with a healthy meal on a typical school day, according to the University of Michigan Health C.S. Mott Children’s Hospital National Poll on Children’s Health.
 Rogel Cancer Center with trees and blue sky
News Release

Rogel Cancer Center names Kaffenberger to deputy director role

The University of Michigan Rogel Cancer Center has named Samuel Kaffenberger, MD, as deputy director for cancer clinical services.
 Bill and Sally Martin stand affectionately with their arms around each other. They appear to be in a high open tower above a city.
Philanthropy News

A Gift to Benefit All: Bill and Sally Martin’s Visionary Support for Sports Medicine

With strong ties to U-M athletics, Bill and Sally Martin have made a gift to kickstart fundraising for the Nathan and Catherine Forbes Sports Medicine Institute at the University of Michigan.
 Microscope images of prostate cancer cells
Health Lab

New drug combination may help treat advanced prostate cancer

University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.